Related Experiment Video
Updated: Mar 22, 2026
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
12.0K
Cell-free circulating tumor DNA in cancer
Zhen Qin1,2, Vladimir A Ljubimov3, Cuiqi Zhou1
1Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, 90048, USA.
Chinese Journal of Cancer
|April 9, 2016
Summary
Liquid biopsies using cell-free circulating tumor DNA (ctDNA) offer a noninvasive way to track cancer. ctDNA analysis shows promise for personalized treatment and early relapse detection, despite ongoing challenges.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Cancer remains a leading cause of death globally, with significant morbidity and mortality.
- Intratumoral heterogeneity poses a major challenge to effective cancer treatment and targeted therapies.
- Current diagnostic and monitoring methods often require invasive procedures.
Purpose of the Study:
- To review the potential of cell-free circulating tumor DNA (ctDNA) as a biomarker for characterizing tumor heterogeneity.
- To explore the clinical applications of ctDNA analysis in cancer management.
- To discuss the challenges and future directions for the clinical adoption of ctDNA biomarkers.
Main Methods:
- Review of current literature on ctDNA analysis and its applications.
- Focus on methods for extracting and analyzing ctDNA from blood samples.
- Discussion of the potential of ctDNA to genotype tumors and monitor disease progression.
Main Results:
- ctDNA analysis enables noninvasive characterization of tumor genetic and epigenetic alterations.
- ctDNA can accurately monitor tumor burden, treatment response, and minimal residual disease.
- Early detection of relapse through ctDNA monitoring can guide treatment decisions.
Conclusions:
- ctDNA is a versatile biomarker with vast potential in personalized oncology.
- Further optimization, standardization, and multicenter trials are necessary for widespread clinical implementation.
- ctDNA analysis may reduce the need for aggressive therapies and improve patient outcomes.
